{
  "ptid_time": "031_S_0568_2006-05-22",
  "img_path": "/data/qiuhui/data/adni/images/031_S_0568/2006-05-22/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 32,069 mm³, 14.3% above the reference mean. With a Z-score of 0.33 (62.8th percentile), this represents normal volume ; hippocampal volume measures 5,079 mm³, 28.6% below the reference mean. With a Z-score of -2.62 (0.4th percentile), this represents significant atrophy; whole brain volume measures 928,543 mm³, 4.7% below the reference mean. With a Z-score of -0.60 (27.6th percentile), this represents normal volume ; entorhinal cortex volume measures 2,191 mm³, 40.3% below the reference mean. With a Z-score of -2.48 (0.7th percentile), this represents significant atrophy; fusiform gyrus volume measures 14,541 mm³, 14.5% below the reference mean. With a Z-score of -1.32 (9.3th percentile), this represents mild atrophy; middle temporal gyrus volume measures 17,779 mm³, 7.3% below the reference mean. With a Z-score of -0.63 (26.4th percentile), this represents normal volume . ",
  "text_data": "Age is 79.8 years. Gender is Female. Education: 16 years. Handedness: Right. Race: White. Medical history: Head, Eyes, Ears, Nose and Throat; Cardiovascular; Musculoskeletal; Allergies or Drug Sensitivities. MMSE: 27.0. Logical Memory: 0.0. APOEε4 alleles: 0.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The patient shows significant atrophy in the hippocampus and entorhinal cortex, both key regions affected in Alzheimer's disease, along with mild atrophy in the fusiform gyrus. Despite normal MMSE (27/30), the structural changes suggest neurodegeneration. The absence of APOE4 reduces genetic risk but does not rule out AD.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely amnestic subtype given hippocampal/entorhinal atrophy).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration, but MCI diagnosis relies on clinical correlation; MMSE is borderline normal).  \n\n*Note: Progression to dementia is likely if atrophy persists/expands. Follow-up with CSF biomarkers (Aβ42, p-tau) or PET imaging would strengthen diagnostic certainty.*",
  "timestamp": "2025-07-26T04:36:29.467832"
}